Abstract
Introduction.Acute renal failure is considered a functional, progressive, oliguric, but reversible kidney disease that occurs due to severe liver disease with hepatic insufficiency. In the development of the syndrome, the leading role is played by the “classical hypothesis of peripheral vasodilation”. Important differentiation in verification of diagnosis is primarily with pseudo hepatorenal syndrome. In the type I (of hepatorenal syndrome) mortality in the first 10 days without an adequate management in intensive care unit is extremely high. The chronic, type II, is a slow process, but requires adequate therapy for up to six months. In general, all clinical manifestations of hepatorenal syndrome are combined into three groups: cardiac insufficiency, systemic vasodilation, and vasoconstriction of renal vessels. The goals of the therapy include restoration of blood flow through the vessels, management of inflammatory processes, prevention of further hepatic tissue destruction, and stabilization of arterial blood pressure in kidney vessels. The core in medical management is adequate albumin infusion and minimal crystalloid support of blood volume, vasopressors, adequate antidote and antibacterial therapy. Additional methods include extracorporeal albumin dialysis to bridge patient to liver transplantation. The orthotopic liver transplantation is the established surgical treatment, as well as transjugular intrahepatic portosystemic shunt (TIPS) or peritoneovenous shunt. Survival rate of patients with hepatorenal syndrome type I on terlipressin in patients with hypoalbuminemia correction is close to 60–75%; survival of with hepatorenal syndrome type II is more favorable in most cases.Methods. The literature review examines diagnostics possibilities of hepatorenal syndrome, importance of timely relevant differential diagnoses and adequate intensive care management.Conclusion. The differential diagnosis between hepatorenal syndrome and pseudo hepatorenal syndrome remains a challenge in routine diagnostic examinations. Intensive care management of such patients requires immediate treatment, which may not be always the most appropriate option. The refore new strategies are needed to improve management of this medical condition.
Highlights
Shipulin Fedor Aleksandrovich — anesthesiology intensivist, Assistant lecturer at the Department of Anesthesiology and Intensive Care Medicine and Disaster Medicine
The differential diagnosis between hepatorenal syndrome and pseudo hepatorenal syndrome remains a challenge in routine diagnostic examinations
Профилактические мероприятия ОППН являются жизненно необходимыми и включают в себя следующий комплекс мероприятий: 1) предупреждение возникновения инфекционных осложнений у пациентов с циррозом печени в качестве применения антибактериальных препаратов пациентам, перенесшим эпизоды желудочно-кишечных кровотечений, а также пациентам со спонтанным бактериальным перитонитом; 2) восполнение альбумина путем в/в введения 6–8 г его препарата в ходе парацентеза больным с асцитом на каждый литр удаленной асцитической жидкости; 3) обоснованное применение лекарственных средств, которые ухудшают функцию почек (аминогликозиды, нестероидные противовоспалительные препараты), и всех мероприятий, которые могут привести к снижению ОЦК; 4) разумная диуретическая коррекция у больных с асцитом ввиду повреждающего действия их высоких доз на почки; 5) исключение применения нефротоксичных препаратов (НПВС, аминогликозиды, диуретики, ингибиторы АПФ, дипиридамол и т.д.) пациентам с заболеваниями печени; 6) преимущественное назначение пентоксифиллина пациентам с острым алкогольным гепатитом
Summary
Acute renal failure is considered a functional, progressive, oliguric, but reversible kidney disease that occurs due to severe liver disease with hepatic insufficiency. In the type I (of hepatorenal syndrome) mortality in the first 10 days without an adequate management in intensive care unit is extremely high. All clinical manifestations of hepatorenal syndrome are combined into three groups: cardiac insufficiency, systemic vasodilation, and vasoconstriction of renal vessels. The goals of the therapy include restoration of blood flow through the vessels, management of inflammatory processes, prevention of further hepatic tissue destruction, and stabilization of arterial blood pressure in kidney vessels. Nagimullin Ramil’ Raisovich — anesthesiology intensivist, Assistant lecturer at the Department of Anesthesiology and Intensive Care Medicine and Disaster Medicine. Shipulin Fedor Aleksandrovich — anesthesiology intensivist, Assistant lecturer at the Department of Anesthesiology and Intensive Care Medicine and Disaster Medicine. Bayalieva Aynagul’ Zholdoshevna — Doctor of Medical Sciences, Head of the Department of Anesthesiology and Intensive Care Medicine and Disaster Medicine
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.